Skip to main content

Table 3 Results of a multivariate survival analysis using a Cox proportional hazards regression mode on the influence of clinicopathological variables including PgR and Ki67

From: Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index

  RFS CSS
Characteristics HR 95% CI P HR 95% CI P
PgR expression
  ≥ 20% Referent
  < 20% 2.33 1.19–4.54 0.013 5.15 2.06–12.85 0.00045
Ki67 labeling index
  ≤ 10% Referent
  > 10 and <30% 0.52 0.18–1.53 0.24 0.28 0.05–1.44 0.13
  ≥ 30% 0.69 0.33–1.47 0.34 0.68 0.29–1.57 0.36
Menopausal status
 Pre- Referent
 Post- 1.24 0.63–2.43 0.53 0.72 0.33–1.61 0.43
Pathological T stage
 T 1–2 Referent
 T 3–4 1.49 0.68–3.25 0.32 1.51 0.58–3.90 0.40
Pathological N stage
 N 0 Referent
 N 1–3 3.16 1.51–6.58 0.0022 2.69 1.04–6.99 0.042
Histological grade
 1,2 Referent
 3 1.31 0.67–2.56 0.43 1.40 0.60–3.25 0.44
Adjuvant chemotherapy
 No Referent
 Yes 1.37 0.71–2.64 0.35 1.25 0.55–2.82 0.59
Adjuvant endocrine therapy
 No Referent
 Yes 1.15 0.39–3.37 0.80 1.20 0.27–5.42 0.81
  1. Abbreviations: RFS recurrence-free survival, CSS cancer-specific survival, HR hazard ratio, 95% Cl 95% Confidence interval, PgR progesterone receptor